<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
<journal-id journal-id-type="hwp">jbc</journal-id>
<journal-id journal-id-type="pmc">jbc</journal-id>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-title-group>
<journal-title>The Journal of Biological Chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9258</issn>
<issn pub-type="epub">1083-351X</issn>
<publisher>
<publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
<publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29559554</article-id>
<article-id pub-id-type="pmc">5950020</article-id>
<article-id pub-id-type="publisher-id">RA118.001753</article-id>
<article-id pub-id-type="doi">10.1074/jbc.RA118.001753</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Bases of Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropsychiatric disease–associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes</article-title>
<alt-title alt-title-type="short">Molecular phenotypes of disease-associated DAT variants</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Herborg</surname>
<given-names>Freja</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Andreassen</surname>
<given-names>Thorvald F.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berlin</surname>
<given-names>Frida</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loland</surname>
<given-names>Claus J.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gether</surname>
<given-names>Ulrik</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor2">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1">From the Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, Panum Institute-Maersk Tower 07.05, University of Copenhagen, DK-2200 Copenhagen, Denmark</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label> To whom correspondence may be addressed. Tel.:
<phone>45-53609699</phone>; E-mail:
<email>frejahh@sund.ku.dk</email>.</corresp>
<corresp id="cor2"><label>2</label> To whom correspondence may be addressed. Tel.:
<phone>45-2384-0089</phone>; E-mail:
<email>gether@sund.ku.dk</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Paul E. Fraser</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>11</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>293</volume>
<issue>19</issue>
<fpage>7250</fpage>
<lpage>7262</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 Herborg et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Herborg et al.</copyright-holder>
<license>
<license-p>Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="zbc01918007250.pdf"></self-uri>
<abstract>
<p>Genetic factors are known to significantly contribute to the etiology of psychiatric diseases such as attention deficit hyperactivity disorder (ADHD) and autism spectrum and bipolar disorders, but the underlying molecular processes remain largely elusive. The dopamine transporter (DAT) has received continuous attention as a potential risk factor for psychiatric disease, as it is critical for dopamine homeostasis and serves as principal target for ADHD medications. Constrain metrics for the DAT-encoding gene, solute carrier family 6 member 3 (<italic>SLC6A3</italic>), indicate that missense mutations are under strong negative selection, pointing to pathophysiological outcomes when DAT function is compromised. Here, we systematically characterized six rare genetic variants of DAT (I312F, T356M, D421N, A559V, E602G, and R615C) identified in patients with neuropsychiatric disorders. We evaluated dopamine uptake and ligand interactions, along with ion coordination and electrophysiological properties, to elucidate functional phenotypes, and applied Zn<sup>2+</sup> exposure and a substituted cysteine–accessibility approach to identify shared structural changes. Three variants (I312F, T356M, and D421N) exhibited impaired dopamine uptake associated with changes in ligand binding, ion coordination, and distinct conformational disturbances. Remarkably, we found that all three variants displayed gain-of-function electrophysiological phenotypes. I312F mediated an increased uncoupled anion conductance previously suggested to modulate neuronal excitability. T356M and D421N both mediated a cocaine-sensitive leakage of cations, which for T356M was potentiated by Zn<sup>2+</sup>, concurrent with partial functional rescue. Collectively, our findings support that gain of disruptive functions due to missense mutations in <italic>SLC6A3</italic> may be key to understanding how dopaminergic dyshomeostasis arises in heterozygous carriers.</p>
</abstract>
<kwd-group>
<kwd>dopamine transporter</kwd>
<kwd>neurotransmitter transport</kwd>
<kwd>monoamine transporter</kwd>
<kwd>genetic polymorphism</kwd>
<kwd>autism</kwd>
<kwd>attention-deficit hyperactivity disorder</kwd>
<kwd>missense mutation</kwd>
<kwd>molecular genetics</kwd>
<kwd>psychiatric disease</kwd>
<kwd>rare variants</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>Danish Council for Independent Research
</funding-source>
<award-id>DFF-4183–00571</award-id>
<award-id>DFF 4004–00097B</award-id>
</award-group>
<award-group id="award2">
<funding-source>
<institution-wrap>
<institution>Lundbeckfonden (Lundbeck Foundation)
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100003554</institution-id>
</institution-wrap>
</funding-source>
<award-id>R181–2014-3090</award-id>
</award-group>
<award-group id="award3">
<funding-source>
<institution-wrap>
<institution>National Institutes of Health
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>P01 DA 12408</award-id>
</award-group>
<award-group id="award4">
<funding-source>
<institution-wrap>
<institution>Novo Nordisk Foundation
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100009708</institution-id>
</institution-wrap>
</funding-source>
<award-id>NNF16OC0023104</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>